This presentation provides a comprehensive overview of Next-Generation Probiotics (NGPs)—microbial strains positioned between traditional probiotics and pharmaceutical-grade live biotherapeutic products (LBPs).
Key topics include:
-Scientific definition and evolution of NGPs
-Regulatory frameworks in the US and EU
-Comparison between traditional probiotics, NGPs, LBPs, and FMT
-Case studies of leading NGP candidates, including Akkermansia muciniphila, Anaerobutyricum soehngenii, Christensenella minuta, Faecalibacterium prausnitzii, and Parabacteroides goldsteinii
-Mechanisms such as SCFA production, immune modulation, GLP-1 induction, and anti-inflammatory LPS signaling
The talk also addresses current limitations, clinical challenges, and future development directions, positioning NGPs as a critical foundation for precision nutrition and microbiome-based therapeutics.